|Bid||39.39 x 1000|
|Ask||49.41 x 800|
|Day's Range||44.50 - 45.97|
|52 Week Range||39.16 - 67.79|
|Beta (3Y Monthly)||3.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.00|
just went public on Dec 7, to an immediate "Strong Buy" rating from eight market analysts. In an impressive open, and the biotech sector's largest IPO, the company raised over $600 million to reach a total value of about $7.4 billion. The company takes a novel approach to the creation of new drugs, basing its research on mRNA, the genetic material that transfers instructions from DNA into completed proteins.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced it has regained worldwide rights to all programs covered under its license and collaboration agreement with Sanofi. The collaboration will not be extended beyond the initial research term, which ended on December 31, 2018, and will conclude in its entirety effective April 1, 2019. As a result, MyoKardia now has global rights to all programs in its portfolio, including lead clinical-stage candidates, mavacamten and MYK-491.
Is MyoKardia, Inc. (NASDAQ:MYOK) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as MyoKardia Inc (NASDAQ:MYOK), with a market capitalization of US$2.5b, rarely draw their attention from the investing community. Read More...
MyoKardia is developing mavacamten for the chronic treatment of hypertrophic cardiomyopathy (HCM), a heritable disease caused by the presence of too many cross-bridges formed between the heart muscle proteins myosin and actin. Mavacamten is intended to normalize this excess cross-bridge formation, which underlies the hypercontractility, or elevated force of contraction, and the reduced compliance, or ability of the left ventricle to relax and fill with oxygenated blood, that are both characteristic of HCM.
One of the first tenants in The Cove at Oyster Point is taking the last building in the South San Francisco development as rents in the region hit new highs.
MyoKardia (MYOK) delivered earnings and revenue surprises of 22.00% and 21.45%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 39 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
An eight-acre Berkeley site near Aquatic Park has hit the market, promoted as a potential 475,000-square-foot office project or life science campus. Commercial brokerage firm JLL (NYSE: JLL) is marketing the site at the foot of Addison Street, east of Interstate 80, to potential developers that could take advantage of a biotech building boom in which hundreds of thousands of square feet are being taken quickly, often months before structures are completed.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of.
Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry.
Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of.
It is one of the largest real estate leases in the Bay Area by traditional drug companies staking out space to establish deeper research and development connections with the region’s hundreds of biotech companies and research universities.
MYOK is a company that is involved with treating cardiovascular disease. Gianakakos said even though one-third of all people die from some form of cardiovascular disease, there's been little innovation in the space. To get to the cause, you need precision medicine, Gianakakos said, and that's what MyoKardia is doing.
Interim PIONEER-OLE Data for Mavacamten Demonstrate Reductions in LVOT Obstruction; Ejection Fraction Maintained above Normal Range First-in-Human Data for MYK-491 in Healthy.
Small VistaGen is building a portfolio of drugs aimed at depression and other mental health conditions, while giant Gilead gets a lower effective tax rate — all that and more in our Health Care Digest.
MyoKardia (MYOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MyoKardia, Inc., (MYOK), a clinical stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that it has entered into a collaboration with 23andMe to advance research for patients with hypertrophic cardiomyopathy (HCM), a progressive and frequently debilitating disease characterized by excessive contractility of the heart. MyoKardia is committed to raising awareness and supporting patients and families suffering from this devastating disease, a commitment shared by 23andMe. “We are proud to continue our history of investing in resources for HCM patients and their caregivers, furthering our core value of Patients First.